Literature DB >> 15084845

Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma.

Ibrahim Khalifeh1, Adnan R Munkarah, Fulvio Lonardo, John M Malone, Robert Morris, W Dwayne Lawrence, Rouba Ali-Fehmi.   

Abstract

The objective of this study was to compare the immunohistochemical profile and clinical course of primary peritoneal serous carcinoma (PPC) and primary ovarian serous carcinoma (OSC). These entities are virtually indistinguishable morphologically, but their differential molecular and clinical features are incompletely characterized. Twenty-nine cases of high-grade, high-stage PPC and 96 cases of stage matched OSCs were compared. PPC was identified based on the criteria proposed by the Gynecologic Oncology Group. The tumors were staged according to International Federation of Gynecology and Obstetrics criteria for ovarian cancer and graded according to World Health Organization criteria. Expression of Cox-2, CD-34, bcl-2, and p53 was compared in the two tumors and correlated with clinical data including stage, age, race, and overall survival. Although the median survival, using Kaplan-Meier test, of patients with OSC (1060 days, 35.3 months) was longer than those with PPC (708 days, 23.6 months) the difference was not statistically significant. However, Cox-2 expression was correlated with microvessel density in PPC (p=0.026) and OSC cases (p=0.005), and high expression of Cox-2 correlated with lower survival rate in OSC cases (p=0.045) but not in PPC cases (p=0.12). These findings, coupled with the morphologic overlap existing between OSC and PPC, support the view that they represent related pathologic entities.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15084845     DOI: 10.1097/00004347-200404000-00011

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  9 in total

Review 1.  Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.

Authors:  Russell Vang; Ie-Ming Shih; Robert J Kurman
Journal:  Adv Anat Pathol       Date:  2009-09       Impact factor: 3.875

2.  Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk.

Authors:  Galina Lurie; Kathryn L Terry; Lynne R Wilkens; Pamela J Thompson; Katharine E McDuffie; Michael E Carney; Rachel T Palmieri; Daniel W Cramer; Marc T Goodman
Journal:  Cancer Causes Control       Date:  2010-06-18       Impact factor: 2.506

3.  Effects of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of ovarian carcinoma in vivo.

Authors:  Wei Li; Hong-he Zhang; Ru-jun Xu; Guang-chao Zhuo; Ye-qing Hu; Juan Li
Journal:  Med Oncol       Date:  2007-10-06       Impact factor: 3.064

4.  Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts.

Authors:  Simone P Pinheiro; Shelley S Tworoger; Daniel W Cramer; Bernard A Rosner; Susan E Hankinson
Journal:  Am J Epidemiol       Date:  2009-04-02       Impact factor: 4.897

5.  Urinary levels of Bcl-2 are elevated in ovarian cancer patients.

Authors:  Nicole S Anderson; Yira Bermudez; Donna Badgwell; Ren Chen; Santo V Nicosia; Robert C Bast; Patricia A Kruk
Journal:  Gynecol Oncol       Date:  2008-11-12       Impact factor: 5.482

6.  Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms.

Authors:  Lauren Patterson Cobb; Stephanie Gaillard; Yihong Wang; Ie-Ming Shih; Angeles Alvarez Secord
Journal:  Gynecol Oncol Res Pract       Date:  2015-05-12

7.  COX-2 expression in ovarian cancer: an updated meta-analysis.

Authors:  Haiming Sun; Xuelong Zhang; Donglin Sun; Xueyuan Jia; Lidan Xu; Yuandong Qiao; Yan Jin
Journal:  Oncotarget       Date:  2017-10-04

Review 8.  Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered.

Authors:  Elie Rassy; Tarek Assi; Stergios Boussios; Joseph Kattan; Julie Smith-Gagen; Nicholas Pavlidis
Journal:  Ann Transl Med       Date:  2020-12

9.  Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies.

Authors:  Cécile Le Page; David G Huntsman; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  Cancers (Basel)       Date:  2010-05-26       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.